PolyNovo (ASX:PNV) logged a total monthly revenue of AU$12.4 million in March, up nearly 49% compared with the same time in 2024, according to a Wednesday filing with the Australian bourse.
Commercial sales climbed over 71% to AU$11.9 million. This was buoyed by record monthly sales of AU$9.3 million in the US, a 93% increase on the year-ago period.
Sales in the year to March surged 31% to AU$84.4 million.
In the same filing, the company said it has roughly 10 months of inventory on hand in the US and does not expect a material impact from the US tariffs based on preliminary assessment.
The medical device company's shares were down 8% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.